Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 3, 2003, Pages 347-353

  Chi, C H ^a   Lin, C Y ^b   Sheu, B S ^a,c   Yang, H B ^a   Huang, A H ^a   Wu, J J ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH SALT; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE; UREA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BITTER TASTE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; NAUSEA; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TASTE DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; UREA BREATH TEST; VOMITING;

AMOXICILLIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; TETRACYCLINE; TREATMENT FAILURE;

EID: 0042825872     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01653.x     Document Type: Article

References (28)

1. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
2. Peterson WL, Fendrick AM, Cave DR, et al. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000; 160: 1285-91.
3. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antibiotics: the MACH1 study. Helicobacter 1996; 1: 138-44.
4. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
5. Veldhuyzen Van Zanten SJO, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
6. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies. Gastroenterology 1999; 116: 248-53.
7. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 79-83.
8. The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
9. Huang AH, Sheu BS, Yang HB, et al. Antimicrobial resistance of H. pylori to the outcome of one-week lansoprazole-based triple therapy. J Formos Med Assoc 2000; 90: 704-9.
10. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-43.
11. O'Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multi-center study. Aliment Pharmacol Ther 2003; 17: 415-20.
12. Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002; 14: 1237-43.
13. Mascitelli L, Pezzetta F. Quadruple treatments for Helicobacter pylori. Lancet 2003; 361: 86.
14. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study. Gastroenterology 2002; 123: 1763-9.
15. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobaeter pylori infection - the Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002; 16: 167-80.
16. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter 2002; 7(Suppl. 1): 43-9.
17. Georgopoulos SD, Ladas SD, Laratapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002; 16: 569-75.
18. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002; 16: 315-24.
19. Sheu BS, Wu JJ, Yang HB, Wu HW, Lin MT. Lactobacillus and bifidobacteria containing yogurt can improve the drug compliance of triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 1669-75.
20. 13C-urea breath test is mandatory to detect H. pylori infection of patients after proton pump inhibitor-based triple therapy. Dig Dis Sci 2000; 45: 1330-6.
21. 13C-urea breath test as early as 15 minutes may correlate well with the bacterial load of H. pylori [abstract]. Gut 1997; 41(Suppl. 2): A84(Abstract).
22. Sheu BS, Yang HB, Wang YL, et al. H. pylori stool antigen assay to screen H. pylori infection and to monitor the outcome of 3-day and 7-day triple therapy for patients with partial gastrectomy. Helicobacter 2002; 7: 199-204.
23. Sheu BS, Wu JJ, Yang HB, Huang AH, Lin XZ. One-week proton pump inhibitor-based triple therapy is effective in eradicating residual H. pylori after failed dual therapy. J Formos Med Assoc 1998; 97: 266-70.
24. Dore MP, Piana A, Carta M, et al. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 635-9.
25. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003; 15: 27-33.
26. Chuang CH, Sheu BS, Huang AH, Yang HB, Wu JJ. Vitamin C and E supplements to amoxicillin-metronidazole-lansoprazole triple therapy may reduce the eradication rate of metronidazole-sensitive H. pylori infection. Helicobacter 2002; 7: 310-6.
27. Wong WM, Wong BC, Lu H, et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002: 16: 793-8.
28. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple/Helicobacter pylori treatment failures. Helicobacter 2003; 8: 90-4.